Goldman Sachs Reiterates Sell Rating on Rocket Pharmaceuticals (RCKT), PT $2,
Tweet Send to a Friend
Goldman Sachs analyst Richard Law reiterated a Sell rating and $2.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
